The prevention and management of cardiovascular complications of chemotherapy in patients with cancer

American Journal of Cardiovascular Drugs

Volumn 5, Issue 4, 2005, Pages 233-243

  Youssef, George ^a   Links, Matthew ^b,c  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c St George Cancer Care   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTHRACYCLINE ANTIBIOTIC AGENT; AROMATASE INHIBITOR; ARSENIC TRIOXIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BRAIN NATRIURETIC PEPTIDE; CISPLATIN DERIVATIVE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; FLUOROPYRIMIDINE; FOLIC ACID; MITOXANTRONE; NAVELBINE; NITRIC ACID DERIVATIVE; PACLITAXEL; RAZOXANE; SEROTONIN 3 ANTAGONIST; TAMOXIFEN; TAXANE DERIVATIVE; THALIDOMIDE; TRASTUZUMAB; TROPONIN T; UNINDEXED DRUG;

ACUTE HEART FAILURE; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; ATRIOVENTRICULAR BLOCK; AUTONOMIC DYSFUNCTION; BIOLOGICAL MONITORING; BONE MARROW SUPPRESSION; BRADYCARDIA; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL VACUOLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DIURETIC THERAPY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ELECTROCARDIOGRAPHY MONITORING; FATALITY; GENETIC POLYMORPHISM; HEART BUNDLE BRANCH BLOCK; HEART DISEASE; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG TERM CARE; LYMPHOMA; METASTASIS; MONOTHERAPY; MORBIDITY; MORTALITY; MUSCLE ATROPHY; MYOCARDITIS; PATHOPHYSIOLOGY; PERICARDITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QRS COMPLEX; QT PROLONGATION; RETREATMENT; REVIEW; SCINTIANGIOGRAPHY; SENSITIVITY AND SPECIFICITY; SINUS BRADYCARDIA; ST SEGMENT ELEVATION; STRESS ECHOCARDIOGRAPHY; THROMBOEMBOLISM; TORSADE DES POINTES; TUMOR VASCULARIZATION; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE;

ANTINEOPLASTIC AGENTS; ARRHYTHMIA; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; CORONARY DISEASE; HUMANS; HYPERTENSION; NEOPLASMS; THROMBOEMBOLISM;

EID: 22244446179     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200505040-00003     Document Type: Review

References (80)

1. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the childhood cancer survivor study. J Clin Oncol 2001; 19 (13): 3163-72
2. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11): 783-92
4. Abraham R, Crump M, MacKinnon J, et al. Alteration in cardiac function following high dose chemotherapy for breast cancer [abstract 336]. Proceedings of the 34th ASCO Annual Meeting; 1998 May 16-19; Los Angeles [online]. Available from URL: http://www.asco.org [Accessed 2005 Jun 2]
5. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukaemia. J Clin Oncol 2001; 19 (18): 3852-60
6. Keefe DL. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? Oncologist 2002; 7 (1): 65-72
7. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993 Aug; 20 (4 Suppl. 3): 1-15
8. Becker K, Erckenbrecht JF, Haussinger D, et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999 Apr; 57 (4): 475-84
9. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 Nov; 349 (19): 1793-802
10. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in cardiolongterm survivors of metastatic testicular cancer. J Clin Oncol 2000 Apr; 18 (8): 1725-32
11. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC [abstract 3646]. Proceedings of the 39th ASCO Annual Meeting; 2003 May 31-Jun 3; Chicago [online]. Available from URL: http://www.asco.org/hurwitz_no3646 [Accessed 2005 Jun 2]
12. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58
13. Steinberg JS, Cohen AJ, Wasserman AG, et al. Acute arrhythmogenicity of doxorubicin administration. Cancer 1987; 60: 1213-8
14. Goldstein LJ, O'Neill A, Sparano JA, et al. LVEF assessment of adjuvant doxorubicin/cyclophosphamide (AC) vs doxorubicin/docetaxel (AT) in early stage breast cancer: cardiac safety results of ECOG 2197 [abstract 73]. The Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol 2003; 22: 19
15. The Criteria Committee of the New York Heart Association. Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis. 6th ed. Boston (MA): Little Brown, 1964
16. Bonneterre JM, Roche H, Kerbrat P, et al. Long-term cardiac follow-up in free of disease patients (pts) after receiving 6 FEC 50 vs 6 FEC 100 (FASG-05 trial) as adjuvant chemotherapy (CT) for node-positive (N+) breast cancer (BC) [abstract 154]. Proceedings of the 38th ASCO Annual Meeting; 2002 May 18-21; Florida [online]. Available from URL: http://www.asco.org [Accessed 2005 Jun 2]
17. Tjeerdsma G, Meinardi MT, van der Graaf WT, et al. Early detection of anthra-cycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 1999; 81 (4): 419-23
18. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003 Jun 1; 97 (11): 2869-79
19. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003 Apr 15; 97 (8): 1991-8
20. Fukumi D, Uchikoba Y, Maeda M, et al. Longitudinal evaluation of anthracycline cardiotoxicity by signal-averaged electrocardiography in children with cancer. Pediatr Int 2002; 44 (2): 134-40
21. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001; 19 (10): 2746-53
22. Gupta M, Thaler HT, Steinherz L. Presence of prolonged dispersion of QT intervals in late survivors of childhood anthracycline therapy. Pediatr Hematol Oncol 2002; 19 (8): 533-42
23. Narula J, Acio ER, Narula N, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 2001; 7 (12): 1347-52
24. Valdes Olmos RA, Carrio I, Hoefnagel CA, et al. High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction. Nucl Med Commun 2002; 23 (9): 871-7
25. Bu'Lock FA, Mott MG, Oakhill A, et al. Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child 1996 Nov; 75 (5): 416-22
26. Stoddard MF, Seeger J, Liddell NE, et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992; 20 (1): 62-9
27. Ocal B, Oguz D, Karademir S, et al. Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo/Doppler indices. Pediatr Cardiol 2002; 23 (5): 522-7
28. Hauser M, Gibson BS, Wilson N. Diagnosis of anthracycline-induced late cardiolong-myopathy by exercise-spiroergometry and stress-echocardiography. Eur J Pediatr 2001; 160 (10): 607-10
29. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiography. N Engl J Med 1979; 300: 278-83
30. Nousiainen T, Jantunen E, Vanninen E, et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2002; 86 (11): 1697-700
31. Mitani I, Jain D, Joska TM, et al. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003; 10 (2): 132-9
32. Palmeri ST, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986; 58: 607-13
33. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13 (5): 699-709
34. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96 (8): 2641-8
35. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36 (2): 517-22
36. Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82 (4): 218-22
37. Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide as a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000; 104 (4): 158-63
38. Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in chil-dren with cancer. Med Pediatr Oncol 2001; 37 (1): 4-9
39. Nousiainen T, Vanninen E, Jantunen E, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002; 251 (3): 228-34
40. Jain KK, Casper ES, Geller NL, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985 Jun; 3 (6): 818-26
41. Bontenbal M, Andersson M, Wildiers J, et al. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer: EORTC Breast Cancer Cooperative Group. Br J Cancer 1998 Jun; 77 (12): 2257-63
42. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous infusion. Ann Intern Med 1982; 96 (2): 133-9
43. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002; 20: 1677-82
44. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15 (4): 1318-32
45. Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardiopro-tection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996 Dec; 14 (12): 3112-20
46. Lopez M, Vici P, Di Lauro K, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998 Jan; 16 (1): 86-92
47. Liu X, Chen Z, Chua CC, et al. Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 2002; 283 (1): H254-63
48. Chakrabarti KB, Hopewell JW, Wilding D, et al. Modification of doxorubicininduced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane). Eur J Cancer 2001; 37 (11): 1435-42
49. Yaris N, Ceviz N, Coskun T, et al. Serum carnitine levels during the doxorubicin therapy: its role in cardiotoxicity. J Exp Clin Cancer Res 2002; 21 (2): 165-70
50. Shaddy RE, Olsen SL, Bristow MR, et al. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 1995; 129 (1): 197-9
51. Silber JH, Cnaan A, Clark B. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines [abstract 1558]. Proceedings of the 38th ASCO Annual Meeting; 2002 May 18-21; Florida [online]. Available from URL: http://www.asco.org [Accessed 2005 Jun 2]
52. Brockstein BE, Smiley C, Al-Sadir J, et al. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant 2000; 25 (8): 885-94
53. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-600
54. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22 (2): 322-9
55. Fuchs IB, Landt S, Beuler H, et al. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Breast Cancer Res Treat 2003; 82 (1): 23-8
56. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459-65
57. Joensuu H, Alanko T, Bono P, et al. Trastuzumab shows no short-term cardiac toxicity when given concomitantly with single agent vinorelbine or docetaxel as adjuvant treatment for early breast cancer [abstract 74]. Proceedings of the 39th ASCO Annual Meeting; 2003 May 31-Jun 3; Chicago [online]. Available from URL: http://www.asco.org [Accessed 2005 Jun 2]
58. Ewer MS, Vooletich M, Valero V, et al. Trastuzumab (herceptin) cardiotoxicity: clinical course and cardiac biopsy correlations [abstract 489]. Proceedings of the 38th ASCO Annual Meeting; 2002 May 18-21; Florida [online]. Available from URL: http://www.asco.org [Accessed 2005 Jun 2]
59. Schwartz CL, Hobbie WL, Truesdell S, et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 1993 Oct; 11 (10): 1906-10
60. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005 Apr 1; 23 (10): 2396-410
61. Ohnishi K, Yoshida H, Shigeno K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002; 16 (4): 617-22
62. Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukaemia. Ann Intern Med 2000; 133 (11): 881-5
63. Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukaemia treated with arsenic trioxide. Blood 2001; 97 (5): 1514-6
64. Benedict CR, Arbogast R, Martin L, et al. Single blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996 Jul; 28 (1): 53-9
65. Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with taxol. J Natl Cancer Inst Monogr 1993; 15: 117-30
66. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991 Sep; 9 (9): 1704-12
67. Saif MW, Szabo E, Grem J, et al. The clinical syndrome of 5-fluorouracil cardiotoxicity [abstract 1613]. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12; 20 (pt1): 404
68. Sorbette F, Simon I, Bonneterre J, et al. Multicenter prospective study of cardiac accidents during treatments with 5-flurouracil. Therapie 1992 Sep-Oct; 47 (5): 371-3
69. Tsavari SN, Kosmas C, Vadiaka M, et al. Cardiotoxicity following different doses and schedules of 5-flurouracil administration for malignancy: a survey of 427 patients. Med Sci Monit 2002 Jun; 8 (6): 151-7
70. Cianci G, Morelli MF, Cannita K, et al. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer 2003 May; 88 (10): 1507-9
71. Schober C, Papageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993 Oct; 72 (7): 2242-7
72. Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994 Mar; 28 (3): 374-8
73. Van Cutsem E, Hoff PM, Blum JL, et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002; 13: 484-5
74. King M, Fernando I. Vascular toxicity associated with cisplatin. Clin Oncol (R Coll Radiol) 2003 Feb; 15 (1): 36-7
75. Miyoshi T, Otsuki T, Omine K, et al. Acute promyelocytic leukemia accompanied by retinoic acid syndrome with complications of acute myocardial infarction and cerebral infarction during treatment with all-trans retinoic acid [in Japanese]. Rinsho Ketsueki 2002 Oct; 43 (10): 954-9
76. Zabernigg A, Gattringer C. Myocardial infarction associated with vinorelbine (Navelbine). Eur J Cancer 1996 Aug; 32A (9): 1618-9
77. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ 1995 Oct; 311 (7011): 977-80
78. Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 2004 Aug; 101 (3): 439-49
79. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005 Jan; 365 (9453): 60-2
80. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab: an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349 (5): 427-34